# Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

Study · id `cardio:ct-nct07007793` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07007793](<https://clinicaltrials.gov/study/NCT07007793>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07007793

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 212 participants.

## Technical summary

Registry record NCT07007793. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-07 (actual); primary completion 2027-07-27 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 212 participants (enrolled count; ClinicalTrials.gov record NCT07007793, source copy `cardio:ctgov-nct07007793-2026-10-16`, retrieved 2026-10-31)
- Started: 2025-08-07 (actual) (ClinicalTrials.gov record NCT07007793, source copy `cardio:ctgov-nct07007793-2026-10-16`, retrieved 2026-10-31)
- Primary completion: 2027-07-27 (anticipated) (ClinicalTrials.gov record NCT07007793, source copy `cardio:ctgov-nct07007793-2026-10-16`, retrieved 2026-10-31)
- Completion: 2028-08-14 (anticipated) (ClinicalTrials.gov record NCT07007793, source copy `cardio:ctgov-nct07007793-2026-10-16`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; China; France; Germany; India; Italy; Japan; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT07007793, source copy `cardio:ctgov-nct07007793-2026-10-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07007793-2026-10-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
- Acronym: BaxPA
- Condition: Primary Hyperaldosteronism
- Intervention (Drug): Baxdrostat
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Primary aldosteronism (`cardio:primary-aldosteronism`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 7013a20c3bc7efb707daafa3d3c6aff64bfd32a77ff3e9f700e72849424d8978
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
